About KAYA17



A Mission to Enable On-site Diagnostic Testing
Building upon our success in identifying food pathogens in produce (fruits and vegetables), we have updated the design of the various components to be able to identify bacteria, virus, pollen and other protein-based pathogens in small specimen samples with very high sensitivity.
Currently, we have developed a solution for the quick and timely diagnosis of the SARS-CoV-2 virus, which has caused the largest pandemic in recent history.
Looking to the future, we are developing rapid anti-body tests for COVID-19 which can evaluate immunity levels in person’s who have received a vaccination. As at present, there is no reliable data to indicate how long immunity from a vaccine will last. Only periodic anti-body testing, over a period of 2-3 years will provide accurate, actionable data. Additionally, rapid tests for other medical conditions such as tests for allergens, certain cancers, infectious diseases such as dengue fever, and other mutations of the SARS virus, will be created by KAYA17. Some basic research for these tests has already been completed.
The KAYA17 Team



Sulatha Dwarakanath, PhD
CEO / Co-Founder
Su has a PhD in Molecular Biology from New York University. She has over 20 years of experience in Product Innovation, Development and Strategy. She was the Founder and Chief Scientific Officer of Nano Science Diagnostics, , a Point of Care focused company.



Srinagesh Satyanarayana, PhD
CTO / Co-Founder
Sri has a PhD in Electrical Engineering from Columbia University. He has more than 25 years of experience in Analog chip design electronic systems, medical devices, and Artificial Intelligence based systems. He was the Founder and CEO of Free Electron Technology.



Camille Troup, PhD
Chief Scientific Officer
Camille received her PhD in Molecular Biology from University of California at San Francisco. She has over 25 years of experience developing and commercializing biomolecular assays and platforms.



Anup Madan
Chief Operations Officer
Anup brings more than 20 years of experience in delivering innovative solutions to support multiple aspects of clinical trials.



Rajan Pillai
VP of Business Development
VP of Business Development
Rajan co-founded Duramed Pharmaceuticals, Trinity Laboratories, and Medi Rx America. He was Managing Director at Peregrine Capital Ltd. As a practicing attorney he has represented the Governments of Indonesia and Sweden and has handled several IPOs of successful early stage enterprises.



Steve Verbinski, MD
Chief Medical Officer
Dr. Verbinski received his Bachelors from Stanford university, M.D from Duke University Medical School. He served as Nocturnist/Hospitalist at San Mateo General Hospital and at Eden Medical Center, Castro Valley CA. He is currently Full time Hospitalist and Co-director at St. Rose Hospital Hayward, CA.



Shreefal Mehta Ph.D., MBA
Chief Commercialization Officer
Shreefal has successfully brought new biotechnology and electronics hardware from lab prototypes to market. He has raised millions of dollars from venture capital, forged strategic partnerships with Fortune 500 companies and driven over $350M in licensing and sales revenues.


